Replimune Group (NASDAQ:REPL) Sets New 12-Month Low on Analyst Downgrade

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares hit a new 52-week low during trading on Tuesday after Barclays downgraded the stock from an overweight rating to an equal weight rating. Barclays now has a $3.00 price target on the stock, down from their previous price target of $17.00. Replimune Group traded as low as $2.68 and last traded at $2.81, with a volume of 86521297 shares trading hands. The stock had previously closed at $12.32.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright cut shares of Replimune Group from a "buy" rating to a "neutral" rating in a research report on Wednesday. JPMorgan Chase & Co. reissued a "neutral" rating and set a $9.00 target price (down from $19.00) on shares of Replimune Group in a research note on Tuesday. Leerink Partnrs lowered shares of Replimune Group from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. Leerink Partners reaffirmed a "market perform" rating and issued a $3.00 price target (down previously from $21.00) on shares of Replimune Group in a report on Tuesday. Finally, Piper Sandler lowered Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 target price on the stock. in a research report on Tuesday. One analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $7.67.

Insider Activity at Replimune Group

In other news, Director Philip Astley-Sparke sold 32,279 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $260,168.74. Following the transaction, the director owned 1,405,071 shares in the company, valued at approximately $11,324,872.26. The trade was a 2.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Sushil Patel sold 25,105 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $202,346.30. Following the completion of the transaction, the chief executive officer directly owned 343,576 shares of the company's stock, valued at approximately $2,769,222.56. This trade represents a 6.81% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 74,907 shares of company stock valued at $603,655. 8.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds have recently modified their holdings of the stock. Swiss National Bank raised its position in Replimune Group by 57.4% in the 4th quarter. Swiss National Bank now owns 103,700 shares of the company's stock worth $1,256,000 after purchasing an additional 37,800 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Replimune Group in the 4th quarter valued at $189,000. American Century Companies Inc. raised its position in shares of Replimune Group by 32.2% during the fourth quarter. American Century Companies Inc. now owns 111,850 shares of the company's stock worth $1,355,000 after acquiring an additional 27,259 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Replimune Group during the fourth quarter valued at $148,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Replimune Group during the fourth quarter valued at $150,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Stock Performance

The firm has a fifty day moving average of $9.27 and a 200-day moving average of $10.24. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.17. The firm has a market cap of $242.83 million, a P/E ratio of -1.03 and a beta of 0.61.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the business posted ($0.25) EPS. Research analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.